p75NTR Ligands for Treament of Traumatic Brain Injury
用于治疗创伤性脑损伤的 p75NTR 配体
基本信息
- 批准号:8195893
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-10-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAnimalsApoptoticBehaviorBehavioralBrainBrain InjuriesBrain-Derived Neurotrophic FactorCause of DeathCell DeathCell Death InhibitionCell Death ProcessCell Differentiation processCell ProliferationCell SurvivalCellsCessation of lifeChronicChronic PhaseClinicalCorticospinal TractsCraniocerebral TraumaDevelopmentDrug KineticsEarly treatmentEffectivenessExhibitsExplosionFocal Brain InjuriesGeneral PopulationGoalsGrowthHippocampus (Brain)HourIn VitroInjuryKnowledgeLeadLifeLigandsMAGED1 geneMAPK8 geneMediatingMemoryModelingMotorMusMyelinNGFR ProteinNatural regenerationNatureNerve Cell SurvivalNerve DegenerationNerve Growth Factor ReceptorsNeuritesNeurologicNeuronsOligodendrogliaOutcomePI3K/AKTPainPathologicPathway interactionsPenetrationPharmaceutical PreparationsPopulationProcessPropertyProto-Oncogene Proteins c-aktRecoveryRehabilitation therapyResearchRoleSignal PathwaySignal TransductionSpinal CordStem cellsStructureSwimmingSymptomsTestingTimeTissuesToxic effectTrainingTraumaTraumatic Brain InjuryTraumatic CNS injuryVeteransWorkaxon regenerationbasecentral nervous system injurycholinergiccombatcontrolled cortical impactdensitydepressive symptomsdisabilitydrug developmenteffective therapyfallsgliogenesisimprovedinjuredinsightknockout animalmind controlmorris water mazenerve stem cellneurogenesisneuronal cell bodyneuronal survivalneurotrophic factorpolypeptidepressurepublic health relevancereceptorreceptor couplingreceptor functionrepairedresearch studyresponsesmall moleculevehicular accident
项目摘要
Project Summary
Traumatic brain injuries (TBIs) constitute a significant and growing percentage of injuries in the veteran
population; sequelae of explosions, motor vehicle accidents and falls. TBI is also a major cause of death
and disability in the general population of the US, particularly in those under 40. Approximately 2% of the
population is living with a chronic TBI-related disability. There are currently no effective protective or
restorative therapies available clinically. In several models of CNS trauma, administration of a
neurotrophin (e.g. BDNF, NGF) protects tissues acutely and promotes longer term recovery. However,
the neurotrophins are poor drugs as they are labile, exhibit poor CNS penetration and may augment cell
death and pain pathways. These properties are due to their polypeptide composition and the stimulation
of intersecting signalling pathways through the activation of multiple receptors. These problems may be
at least partially circumvented through the use of recently discovered small, stable, non-peptidyl drug-like
compounds (designated LM11A) that potently promote neuronal survival through selective interactions
with the neurotrophin receptor p75NTR, inhibit proNGF-induced death, and promote neural progenitor cell
proliferation. p75NTR and proNGF have been implicated in several neurodegenerative processes,
including the apoptotic death of oligodendrocytes in the spinal cord and corticospinal tract neurons in the
brain following trauma. We hypothesize that the LM11A compounds will inhibit cell death occurring hours
to days following a traumatic injury, and further, that effects on neurogenesis and neurite plasticity will
improve brain structure and function at times remote (weeks, months) from the injury. In addition, we
postulate that these effects will occur in association with the promotion of survival and differentiative
signaling (e.g. via AKT, ERK, NF¿B pathways) by the compound, and the suppression of death signaling
(e.g. via JNK activation). The specific aims of this proposal are to: 1) to examine changes in cell signaling
associated with the inhibition of cell death by a p75NTR-directed compound (LM11A-31) in the context of
focal brain trauma, 2) to determine the responses of a model of focal brain trauma to LM11A-31 given in
an early/delayed fashion, and in the late/chronic phase, and 3) to determine the roles of p75NTR following
injury. Towards these aims, a controlled cortical impact (CCI) model of brain trauma in mice will be used
to assess the effects of the LM11A-31 on cell survival and signalling, neuro- and gliogenesis, cholinergic
neurite density, and 'depressive' (Porsolt Forced Swim Test) and memory (Morris Water Maze)
behaviors in animals treated immediately, up to 24 hrs, or beginning 2 weeks following injury. To further
examine p75NTR function and compound mechanisms in TBI, cell death, process dystrophy and
neurogenesis will be evaluated in p75NTR deficient animals subjected to CCI. These studies will provide
information important for the eventual application of these or related compounds to clinical head trauma,
and will advance our knowledge of the roles of p75NTR in pathologic states. The overall goal of this
research is to advance the application of these neurotrophic compounds to the treatment of brain trauma
and other conditions.
项目摘要
创伤性脑损伤(TBIs)构成了一个显着的和不断增长的百分比受伤的退伍军人
人口;爆炸、机动车事故和福尔斯坠落的后遗症。TBI也是死亡的主要原因
和残疾在美国的一般人口,特别是在那些40岁以下。大约2%的
患有慢性TBI相关残疾的人口。目前没有有效的保护或
临床上可用的恢复疗法。在几种CNS创伤模型中,
神经营养因子(例如BDNF、NGF)急性保护组织并促进长期恢复。然而,在这方面,
神经营养素是不良药物,因为它们是不稳定的,表现出差的CNS渗透性,并可增加细胞
死亡和疼痛的路径。这些特性是由于它们的多肽组成和刺激
通过激活多个受体的交叉信号通路。这些问题可能是
通过使用最近发现的小的、稳定的、非肽类药物至少部分地避免了
通过选择性相互作用有效促进神经元存活的化合物(命名为LM 11 A)
与神经营养因子受体p75 NTR,抑制proNGF诱导的死亡,并促进神经祖细胞
增殖p75 NTR和proNGF与几种神经退行性过程有关,
包括脊髓中的少突胶质细胞和脊髓中的皮质脊髓束神经元的凋亡性死亡。
脑外伤后。我们假设LM 11 A化合物将抑制细胞死亡发生数小时,
到创伤性损伤后的几天,并且进一步地,对神经发生和神经突可塑性的影响将
在远离损伤的时间(数周,数月)改善大脑结构和功能。另外我们
假设这些作用将与促进存活和分化相关,
信号传导(例如通过AKT、ERK、NF B途径),以及抑制死亡信号传导
(e.g.通过JNK激活)。这项建议的具体目标是:1)检查细胞信号传导的变化
与p75 NTR导向的化合物(LM 11 A-31)抑制细胞死亡相关的
2)确定局灶性脑创伤模型对LM 11 A-31的反应,
早期/延迟方式,以及晚期/慢性阶段,和3)确定p75 NTR在以下过程中的作用
损伤为了实现这些目标,将使用小鼠脑创伤的受控皮质撞击(CCI)模型
为了评估LM 11 A-31对细胞存活和信号传导、神经元和神经胶质细胞生成、胆碱能神经元和神经胶质细胞生成的影响,
神经突密度、“抑郁”(Porsolt强迫游泳试验)和记忆(Morris水迷宫)
在损伤后立即、长达24小时或开始2周治疗的动物中的行为。进一步
研究p75 NTR功能和复合机制在TBI,细胞死亡,过程营养不良和
将在经历CCI的p75 NTR缺陷动物中评价神经发生。这些研究将提供
对于这些或相关化合物最终应用于临床头部创伤的重要信息,
并将促进我们对p75 NTR在病理状态中的作用的认识。这个项目的总体目标是
研究的目的是促进这些神经营养化合物在脑外伤治疗中的应用
和其它条件。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN M. MASSA其他文献
STEPHEN M. MASSA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN M. MASSA', 18)}}的其他基金
ShEEP request for Real-Time Quantitative PCR machine
ShEEP 要求提供实时定量 PCR 机
- 批准号:
9212034 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Trk Ligands for Treatment of Traumatic Brain Injury
用于治疗创伤性脑损伤的 Trk 配体
- 批准号:
8736250 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Trk Ligands for Treatment of Traumatic Brain Injury
用于治疗创伤性脑损伤的 Trk 配体
- 批准号:
9280751 - 财政年份:2010
- 资助金额:
-- - 项目类别:
p75NTR Ligands for Treament of Traumatic Brain Injury
用于治疗创伤性脑损伤的 p75NTR 配体
- 批准号:
8394596 - 财政年份:2009
- 资助金额:
-- - 项目类别:
p75NTR Ligands for Treament of Traumatic Brain Injury
用于治疗创伤性脑损伤的 p75NTR 配体
- 批准号:
7919403 - 财政年份:2009
- 资助金额:
-- - 项目类别:
p75NTR Ligands for Treament of Traumatic Brain Injury
用于治疗创伤性脑损伤的 p75NTR 配体
- 批准号:
7795053 - 财政年份:2009
- 资助金额:
-- - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant